Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Cell and gene therapy manufacturing

- PMLiVE

Novartis wins partial reprieve for Gilenya in Germany

IQWiG now minded to give a broader recommendation for the multiple sclerosis pill

- PMLiVE

Novartis gets early approval for heart failure drug Entresto

It is the first worldwide indication for the in-class neprilysin inhibitor

- PMLiVE

90TEN and ICG win market research award at Communiqué 2015

Execution of 'Wheals of Despair' campaign for Novartis praised by judges

Novartis day

Novartis heart drug may see novel pricing plan

Swiss firm looking to risk share with payers based on clinical outcomes

- PMLiVE

Novartis launches Apple Watch app for the visually impaired

Upgraded ViaOpta app already works on iPhone and Android phones

Novartis building

Novartis buys chronic pain specialist Spinifex Pharma

Pays $200m for the Australian pharmaceutical company

- PMLiVE

Ten new medicines recommended in Europe

Includes double approvals for rare disease specialist Alexion and Novartis

- PMLiVE

Google unveils wearable health tracker

Builds on the tech giant’s foray into the health and wellness sector

- PMLiVE

Novartis aims to lead immuno-oncology category

Firm believes its immuno-oncology pipeline will help it overtake leader Roche

- PMLiVE

Pharma set for a strong 2015 as drug sales jump

Industry looking to put the recent ‘horror’ patent expiry years behind it

- PMLiVE

GSK sets up new research initiative in Seattle

Will use an independent research base to understand how cells work

- PMLiVE

Novartis gets FDA nod for rare blood disorder drug

Promacta will provide a treatment option for children over 6 years old

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links